MX2015001068A - Analisis, diagnostico y pronostico de autismo y otros trastornos del desarrollo. - Google Patents

Analisis, diagnostico y pronostico de autismo y otros trastornos del desarrollo.

Info

Publication number
MX2015001068A
MX2015001068A MX2015001068A MX2015001068A MX2015001068A MX 2015001068 A MX2015001068 A MX 2015001068A MX 2015001068 A MX2015001068 A MX 2015001068A MX 2015001068 A MX2015001068 A MX 2015001068A MX 2015001068 A MX2015001068 A MX 2015001068A
Authority
MX
Mexico
Prior art keywords
autism
gene
ages
signature matrix
years
Prior art date
Application number
MX2015001068A
Other languages
English (en)
Inventor
Eric Courchesne
Tiziano Pramparo
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2015001068A publication Critical patent/MX2015001068A/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Abstract

La invención proporciona un método y sistema que combina mediciones y análisis de datos funcionales genómicos y genéticos, proteómicos, de neuroimaginología anatómica, de neuroimaginología funcional, del comportamiento y clínicos para el análisis, diagn6stico o pronóstico de población pediátrica con autismo. Más específicamente, la invención proporciona una prueba de genes ponderados y características para el autismo que usa una matriz característica de genes ponderados para la comparación con una base de datos de referencia de individuos saludables y aquejados. La invención también proporciona características de valor de expresión génica normalizadas para la comparación con una base de datos de referencia. Asimismo, la invención combina o bien el análisis de genes ponderados o de genes normalizados con comparaciones con una matriz característica de redes de genes, una matriz característica multimodal y una matriz característica de rasgos secundarios para la precisión mejorada en el análisis, diagnóstico y pronóstico de la relevancia para el autismo, especialmente para recién nacidos, bebés con edades que van del nacimiento al año, bebés mayores con edades de 1 a 2 años, bebés mayores con edades de 2 a 3 años y niños pequeños con edades de 3 a 4 años.
MX2015001068A 2012-07-26 2013-07-25 Analisis, diagnostico y pronostico de autismo y otros trastornos del desarrollo. MX2015001068A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261675928P 2012-07-26 2012-07-26
PCT/US2013/052094 WO2014018774A1 (en) 2012-07-26 2013-07-25 Screening, diagnosis and prognosis of autism and other developmental disorders

Publications (1)

Publication Number Publication Date
MX2015001068A true MX2015001068A (es) 2015-04-08

Family

ID=49997839

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001068A MX2015001068A (es) 2012-07-26 2013-07-25 Analisis, diagnostico y pronostico de autismo y otros trastornos del desarrollo.

Country Status (10)

Country Link
US (1) US10002230B2 (es)
EP (1) EP2877605A4 (es)
CN (1) CN104662173A (es)
AU (1) AU2013295732A1 (es)
BR (1) BR112015001642A2 (es)
CA (1) CA2879359A1 (es)
EA (1) EA201590175A1 (es)
HK (1) HK1205767A1 (es)
MX (1) MX2015001068A (es)
WO (1) WO2014018774A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2015112162A1 (en) * 2014-01-24 2015-07-30 Hewlett-Packard Development Company, L.P. Identifying deviations in data
US10255337B2 (en) * 2015-03-31 2019-04-09 Change Healthcare Holdings, Llc Health care information system and method for transforming health care data with a transformation pipeline
JP7002037B2 (ja) 2015-07-01 2022-02-04 デューク・ユニヴァーシティ 急性呼吸器感染症を診断および処置するための方法
WO2017083310A1 (en) * 2015-11-09 2017-05-18 Inkaryo Corporation A normalization method for sample assays
CN105652016A (zh) * 2016-01-28 2016-06-08 深圳大学 一种孤独症检测标志物及其检测方法
US20190088365A1 (en) * 2016-03-01 2019-03-21 Sentimetrix, Inc Neuropsychological evaluation screening system
CN106381330A (zh) * 2016-08-30 2017-02-08 张建华 一种检测交通性脑积水易感性的引物及试剂盒
KR101887161B1 (ko) 2016-10-10 2018-08-09 오동훈 자폐 스펙트럼 장애의 진단용 조성물, 이를 포함하는 마이크로어레이 및 이를 검출하는 방법
US20180251849A1 (en) * 2017-03-03 2018-09-06 General Electric Company Method for identifying expression distinguishers in biological samples
US10912801B2 (en) 2017-03-13 2021-02-09 Duke University Methods for the treatment of autism spectrum disorders
CN107058526B (zh) * 2017-03-21 2020-12-29 济南大学 一种基于基因对共表达模式动态关联解析玉米籽粒类胡萝卜素代谢调控机制的方法
CN108784666B (zh) * 2017-05-04 2023-01-13 深圳市生码医疗科技有限公司 连续监测心血管的精准医疗系统及数据处理方法
CN107169274A (zh) * 2017-05-05 2017-09-15 深圳市心智心理测量技术研究所有限公司 阿斯伯格综合症问卷处理方法、装置、设备及存储介质
US10327637B2 (en) * 2017-06-08 2019-06-25 Fdna Inc. Systems, methods, and computer-readable media for patient image analysis to identify new diseases
WO2019099753A1 (en) * 2017-11-15 2019-05-23 The Translational Genomics Research Institute Biomarker proxy tests and methods for standard blood chemistry tests
CN110097240A (zh) * 2018-01-30 2019-08-06 郑州大学西亚斯国际学院 一种基于互联网的创业潜质情景模拟测评系统及方法
CN109142744A (zh) * 2018-07-26 2019-01-04 珠海中科先进技术研究院有限公司 一种自闭症谱系障碍诊断试剂盒
CN109872776B (zh) * 2019-02-14 2023-06-09 辽宁省肿瘤医院 一种基于加权基因共表达网络分析对胃癌潜在生物标志物的筛选方法及其应用
US20220208386A1 (en) * 2019-04-05 2022-06-30 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic for maternal risk of having a child with autism spectrum disorder
CN110232974B (zh) * 2019-04-22 2021-10-01 福建医科大学附属第一医院 多发性骨髓瘤综合风险评分方法
US11468994B2 (en) * 2019-06-28 2022-10-11 Cerner Innovation, Inc. Pneumonia readmission prevention
US11449792B2 (en) * 2019-07-03 2022-09-20 Kpn Innovations, Llc. Methods and systems for generating a supplement instruction set using artificial intelligence
US11688505B2 (en) * 2019-07-03 2023-06-27 Kpn Innovations, Llc. Methods and systems for generating a supplement instruction set using artificial intelligence
CN110331164B (zh) * 2019-08-05 2021-04-06 北京大学人民医院(北京大学第二临床医学院) Lilra3基因敲入小鼠的打靶载体和lilra3基因敲入小鼠的构建方法
JP2022544604A (ja) * 2019-08-16 2022-10-19 テンパス・ラボズ・インコーポレイテッド がん検体において細胞経路調節不全を検出するためのシステム及び方法
CN110840468B (zh) * 2019-11-18 2022-04-22 深圳市铱硙医疗科技有限公司 自闭症风险评估方法及装置、终端设备、存储介质
WO2021152600A1 (en) * 2020-02-02 2021-08-05 Cell-El Therapeutics Ltd. Methods and kits for characterizing and identifying autism spectrum disorder
KR102313457B1 (ko) * 2020-02-27 2021-10-15 이화여자대학교 산학협력단 알츠하이머병 치매 특이적 유전자 nhlrc4 및 이를 이용한 알츠하이머병 치매 예측
CN111723867A (zh) * 2020-06-22 2020-09-29 山东大学 一种网络游戏迷恋度智能评估系统及方法
US20220076784A1 (en) * 2020-09-04 2022-03-10 10X Genomics, Inc. Systems and methods for identifying feature linkages in multi-genomic feature data from single-cell partitions
CN112837822B (zh) * 2020-09-24 2023-05-02 广州市疾病预防控制中心(广州市卫生检验中心、广州市食品安全风险监测与评估中心、广州医科大学公共卫生研究院) 预测covid-19患者发生轻至重度进展的标志物及试剂盒和建立方法
CN112802546B (zh) * 2020-12-29 2024-05-03 中国人民解放军军事科学院军事医学研究院 一种生物状态表征方法、装置、设备及存储介质
CN113160986B (zh) * 2021-04-23 2023-12-15 桥恩(北京)生物科技有限公司 用于预测全身炎症反应综合征发展的模型构建方法及系统
CN114446476B (zh) * 2022-01-28 2023-02-17 中南大学湘雅二医院 孤独症治疗效果预测模型构建方法、预测方法及装置
WO2023198176A1 (en) * 2022-04-15 2023-10-19 Xinhua Hospital Affiliated To Shanghai Jiaotong University School Of Medicine Prediction of the treatment response to bumetanide in subject with autism spectrum disorder
CN117409855B (zh) * 2023-10-25 2024-04-26 苏州卫生职业技术学院 一种肝细胞癌患者错配修复相关预后模型及其构建、验证方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
JP4938371B2 (ja) * 2006-07-04 2012-05-23 独立行政法人理化学研究所 自閉症素因の検出方法
US8173369B2 (en) * 2008-05-15 2012-05-08 The Regents Of The University Of California Peripheral gene expression biomarkers for autism
WO2010147714A1 (en) * 2009-06-16 2010-12-23 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2011079299A1 (en) * 2009-12-23 2011-06-30 The George Washington University Compositions and methods for identifying autism spectrum disorders
CA2791905A1 (en) * 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
WO2011112961A1 (en) * 2010-03-12 2011-09-15 Children's Medical Center Corporation Methods and compositions for characterizing autism spectrum disorder based on gene expression patterns
EP2385134A1 (en) * 2010-05-07 2011-11-09 Ludwig-Maximilians-Universität München Risk prognosis method for chronic lymphocytic leukemia

Also Published As

Publication number Publication date
WO2014018774A1 (en) 2014-01-30
AU2013295732A1 (en) 2015-02-05
EP2877605A4 (en) 2016-03-02
CA2879359A1 (en) 2014-01-30
HK1205767A1 (en) 2015-12-24
EP2877605A1 (en) 2015-06-03
US10002230B2 (en) 2018-06-19
EA201590175A1 (ru) 2015-06-30
BR112015001642A2 (pt) 2017-07-04
US20150227681A1 (en) 2015-08-13
CN104662173A (zh) 2015-05-27

Similar Documents

Publication Publication Date Title
MX2015001068A (es) Analisis, diagnostico y pronostico de autismo y otros trastornos del desarrollo.
Kruszka et al. 22q11. 2 deletion syndrome in diverse populations
Venkatasubramanian et al. Biomarkers in psychiatry-a critique
Seth et al. Maternal prenatal mental health and placental 11β-HSD2 gene expression: initial findings from the mercy pregnancy and emotional wellbeing study
Nygren et al. The prevalence of autism spectrum disorders in toddlers: a population study of 2-year-old Swedish children
Santos et al. Long-lasting maternal depression and child growth at 4 years of age: a cohort study
Lowe et al. Maternal obesity during pregnancy as a risk for early-life asthma
Delhalle et al. A roadmap towards personalized immunology
Wijga et al. Sex differences in asthma during the first 8 years of life: the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study
Pacheco et al. Development of a validated blood test for nickel sensitization
Hodyl et al. Cord blood DNA methylation biomarkers for predicting neurodevelopmental outcomes
Myint et al. The International Community-Acquired Pneumonia (CAP) Collaboration Cohort (ICCC) study: rationale, design and description of study cohorts and patients
Dinkler et al. Etiology of the broad avoidant restrictive food intake disorder phenotype in Swedish twins aged 6 to 12 years
Clarke Congenital fibre type disproportion–a syndrome at the crossroads of the congenital myopathies
Depke et al. Sexual health assessment and counseling: oncology nurses' perceptions, practices, and perceived barriers.
Park et al. Prenatal exposure to traffic-related air pollution and the DNA methylation in cord blood cells: MOCEH study
Berliner Ethical dilemmas in genetics and genetic counseling: principles through case scenarios
Lee et al. Association between gut microbiota and emotional-behavioral symptoms in children with attention-deficit/hyperactivity disorder
Sullivan et al. Measuring the effect of asthma control on exacerbations and health resource use
Moberg et al. Fetal alcohol syndrome surveillance: age of syndrome manifestation in case ascertainment
Vercelli et al. Strength in numbers: the quest for asthma genes
Ciprandi Serum IgE as biomarker for predicting allergen immunotherapy effectiveness
Schmidt et al. Implementing MR imaging into clinical routine screening in patients with psychosis?
Zelco et al. Insights into sex and gender differences in brain and psychopathologies using big data
Hutchins et al. Quality control metrics for whole blood transcriptome analysis in the Parkinson’s progression markers initiative (PPMI)